Cellectis

Cellectis Pre-Tax Margin

The Pre-Tax Profit Margin of Cellectis (ALCLS.PA) as of Oct 26, 2026 is -102.35 %. In the previous year, Pre-Tax Profit Margin was -88.57 % — a change of 15.56% (lower).

Pre-Tax Margin

-102.35 %

YoY

15.56%

Last updated:

Pre-Tax Profit Margin of Cellectis is 2025 -102.35 % . Pre-Tax Profit Margin of Cellectis was 2024 -88.57 % . It decreases by 15.56% lower compared to the previous year.

The Cellectis Pre-Tax Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Pre-Tax Margin
Date
Pre-Tax Margin
Jan 1, 2018
-693.84 USD
Jan 1, 2019
-758.47 USD
Jan 1, 2020
-131.82 USD
Jan 1, 2021
-131.82 USD
Jan 1, 2022
-514.32 USD
Jan 1, 2023
-15,425.70 USD
Jan 1, 2024
-88.57 USD
Jan 1, 2025
-102.35 USD
The Cellectis Pre-Tax Margin history
YEARPre-Tax MarginYoY
-102.35 %+15.56%
-88.57 %-99.43%
-15,425.70 %+2,899.22%
-514.32 %+290.16%
-131.82 %0.00%
-131.82 %-82.62%
-758.47 %+9.31%
-693.84 %+68.56%
-411.63 %+174.25%
-150.09 %+270.91%
-40.47 %-572.80%
8.56 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cellectis Stock analysis

What does Cellectis do? Cellectis SA is an emerging biotechnology company focused on developing innovative therapies for cancer and other serious diseases. It was founded in 1999 by a French scientist named André Choulika and is headquartered in Paris, France. Cellectis' main business is the development of CAR-T cell therapies, which involve reprogramming immune cells to target specific types of cancer. This method specifically targets cancer cells while leaving healthy cells unaffected, offering a more precise and less invasive alternative to traditional cancer treatments. Cellectis' business model is centered around developing tailored cancer treatments for individual patients using its Cellectis System, a combination of genomic and cellular technologies. The company also has subsidiaries and joint ventures focusing on different segments of the biopharmaceutical market, such as Calyxt, which specializes in genetic modification of crops, and Ectycell, which focuses on developing cell therapies for rare blood diseases. Cellectis offers a range of products and services focused on cancer drug development, including cell therapies, genetic testing, clinical trials, and consulting services. Its products and services are tailored to the individual needs of patients and aim to revolutionize cancer treatment through advanced technology and innovative approaches. In summary, Cellectis is an innovative biotechnology company successfully focusing on developing tailored cancer therapies. With its wide range of products and services catering to patient needs, and with advancements in cancer therapy, Cellectis is well positioned to become a key player in the biopharmaceutical industry. Cellectis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cellectis stock

Pre-Tax Profit Margin of Cellectis is -102.35 % in 2025.

Pre-Tax Profit Margin of Cellectis changed from -88.57 % to -102.35 %, representing a 15.56% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Pre-Tax Profit Margin Cellectis since 2006 – with annual values, charts, and detailed analysis.

Pre-tax margin measures the percentage of revenue remaining after all expenses except income taxes. It isolates operational and financial performance from tax effects.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Pre-Tax Profit Margin's Cellectis with sector peers and the industry average to assess whether it is attractive.

To evaluate Pre-Tax Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Pre-Tax Profit Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Cellectis

All Key Metrics — Cellectis